Search

Your search keyword '"Sarcoma/mortality"' showing total 3 results
Start Over Descriptor "Sarcoma/mortality"
3 results on '"Sarcoma/mortality"'

1. Soft Tissue Sarcomas of the Thoracic Wall: More Prone to Higher Mortality, and Local Recurrence—A Single Institution Long-Term Follow-up Study

Author

Peter Holmberg Jørgensen, Tine Rytter Soerensen, Anette Hoejsgaard, Thomas Baad-Hansen, Mathias Raedkjaer, and Akmal Safwat

Subjects
Male, Surgical margin, Soft Tissue Neoplasms, TRUNK WALL, PROGNOSTIC-FACTORS, 0302 clinical medicine, Registries, 030212 general & internal medicine, Single institution, MARGINS, Neoplasm Recurrence, Local/epidemiology, Aged, 80 and over, OUTCOMES, Margins of Excision, Soft tissue, Sarcoma, Sarcoma/mortality, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Prognosis, medicine.anatomical_structure, Oncology, SURGICAL-TREATMENT, 030220 oncology & carcinogenesis, SURVIVAL, Female, Radiology, CHEST-WALL, Thoracic wall, Research Article, Adult, medicine.medical_specialty, RESECTION, Soft Tissue Neoplasms/mortality, Article Subject, Adolescent, Long term follow up, lcsh:RC254-282, Young Adult, 03 medical and health sciences, medicine, Humans, EXTREMITY, Thoracic Wall, Aged, Retrospective Studies, Thoracic Neoplasms/mortality, business.industry, Retrospective cohort study, Thoracic Neoplasms, medicine.disease, Survival Analysis, Confidence interval, Thoracic Wall/pathology, FRENCH-FEDERATION, Surgery, Neoplasm Grading, Neoplasm Recurrence, Local, business, Follow-Up Studies
Abstract

Objectives. This study aims to assess the impact of surgical margin and malignancy grade on overall survival (OS) and local recurrence free rate (LRFR) for soft tissue sarcomas (STS) of the thoracic wall. Methods. This retrospective cohort study identified 88 patients, diagnosed and treated surgically for a nonmetastatic STS located in the thoracic wall between 1995 and 2013, using the population based and validated Aarhus Sarcoma Registry and Danish Sarcoma Registry. The Kaplan-Meier method was used to estimate OS and LRFR. Multivariate Cox analyses were used to determine prognostic factors for OS and LRFR. Results. The 5-year OS was 55% (95% confidence interval (CI): 0.44-0.65) and 5-year LRFR was 77% (95% CI: 0.67-0.85). High malignancy grade and intralesional/marginal resection were identified as negative predictors for OS. High grade was the only prognostic factor associated with a lower LRFR. Conclusions. In this large, single institution, study tumor grade was the key predictor for OS and LRFR. Surgical margin only statistically significantly influenced mortality, not local recurrence.

Published
2019

2. Long-term results of the Global Modular Replacement System tumor prosthesis for reconstruction after limb-sparing bone resections in orthopedic oncologic conditions:Results from a national cohort

Author

Yilmaz, Müjgan, Sørensen, Michala S, Saebye, Casper, Baad-Hansen, Thomas, Petersen, Michael M., Yilmaz, Müjgan, Sørensen, Michala S, Saebye, Casper, Baad-Hansen, Thomas, and Petersen, Michael M.

Abstract

BACKGROUND AND OBJECTIVES: We investigated implant revision, implant failure, and amputation risk after limb-sparing bone tumor surgery using the Global Modular Replacement System (GMRS) tumor prosthesis in patients suffering from bone sarcomas (BS), giant cell tumors (GCT), or metastatic bone disease (MBD).MATERIAL AND METHODS: A retrospective study of a nationwide consecutive cohort (n = 119, 47 [12-81] years, M/F = 65/54) having limb-sparing surgery and reconstruction using the GMRS tumor prosthesis due to bone tumors (BS/GCT/MBD = 70/8/41) from 2005 to 2013. Anatomical locations were as followed: distal femur (n = 49), proximal femur (n = 41), proximal tibia (n = 26), or total femur (n = 3). Kaplan-Meier survival analysis and competing risk analysis with death as a competing risk were used for statistical analysis.RESULTS: For BS and GCT patients, 5-year patient survival was 72% (95% confidence interval [CI]: 59-85%) and for MBD 33% (95% CI: 19-48%). Thirty-two patients underwent revision surgery (5-year revision incidence 14%; 95% CI: 8-21%). Twelve patients had revision of bone-anchored parts (implant failure) with a 5-year revision incidence 6% (95% CI: 2-10%). Ten amputations were performed due to local relapse (n = 9) or recurrent infections (n = 1) with a 5-year incidence of amputation: 8% (95% CI: 3-13%).CONCLUSIONS: We identified a low risk of revision and amputation when using the GMRS tumor prosthesis for limb-sparing bone tumor.

Published
2019

3. Soft tissue sarcomas of the trunk wall (STS-TW): a study of 343 patients from the French Sarcoma Group (FSG) database

Author

F. Collin, P. Terrier, I. Valo, J. J. Michels, Louis Guillou, B. Marques, Sébastien Salas, M. Trassard, J.-M. Coindre, V. Brouste, Binh Bui, E. Stoeckle, Agnès Leroux, Dominique Ranchère-Vince, and Yves-Marie Robin

Subjects
Adult, Male, Multivariate analysis, Adolescent, medicine.medical_treatment, education, Aged, Aged, 80 and over, Databases as Topic, Female, Humans, Middle Aged, Sarcoma/mortality, Sarcoma/pathology, Survival Analysis, Young Adult, computer.software_genre, Abdominal wall, medicine, Database, business.industry, Soft tissue sarcoma, Soft tissue, Cancer, Sarcoma, Hematology, medicine.disease, Radiation therapy, medicine.anatomical_structure, Oncology, business, computer, Thoracic wall
Abstract

BACKGROUND: Soft tissue sarcomas of the trunk wall (STS-TW) are usually studied together with soft tissue sarcomas of other locations. We report a study on STS-TW forming part of the French Sarcoma Group database. PATIENTS AND METHODS: Three hundred and forty-three adults were included. We carried out univariate and multivariate analysis for overall survival (OS), metastasis-free survival (MFS) and local recurrence-free survival (LRFS). RESULTS: Tumor locations were as follows: thoracic wall, 82.5%; abdominal wall, 12.3% and pelvic wall, 5.2%. Median tumor size was 6.0 cm. The most frequent tumor types were unclassified sarcoma (27.7%) and myogenic sarcoma (19.2%). A total of 44.6% of cases were grade 3. In all, 21.9% of patients had a previous medical history of radiotherapy (PHR). Median follow-up was 7.6 years. The 5-year OS, MFS and LRFS rates were 60.4%, 68.9% and 58.4%, respectively. Multivariate analysis retained PHR and grade for predicting LRFS and PHR, size and grade as prognostic factors of MFS. Factors influencing OS were age, size, PHR, depth, grade and surgical margins. The predictive factors of incomplete response were PHR, size and T3. CONCLUSIONS: Our results suggest similar classical prognostic factors as compared with sarcomas of other locations. However, a separate analysis of STS-TW revealed a significant poor prognosis subgroup of patients with PHR.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results